Identification

Name
Doxazosin
Accession Number
DB00590  (APRD00474)
Type
Small Molecule
Groups
Approved
Description

Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.

Structure
Thumb
Synonyms
  • 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
  • 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
  • Doxazosina
  • Doxazosine
  • Doxazosinum
Product Ingredients
IngredientUNIICASInChI Key
Doxazosin mesylate86P6PQK0MU77883-43-3VJECBOKJABCYMF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarduraTablet4 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet1 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet8 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet2 mg/1OralRoerig1990-11-02Not applicableUs
Cardura XLTablet, multilayer, extended release4 mg/1OralRoerig2005-02-22Not applicableUs
Cardura XLTablet, multilayer, extended release8 mg/1OralRoerig2005-02-22Not applicableUs
Cardura-1 Tab 1mgTablet1 mgOralPfizer1992-12-31Not applicableCanada
Cardura-2 Tab 2mgTablet2 mgOralPfizer1992-12-31Not applicableCanada
Cardura-4 Tab 4mgTablet4 mgOralPfizer1992-12-31Not applicableCanada
Dom-doxazosinTablet1 mgOralDominion Pharmacal2004-05-26Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxazosinTablet1 mgOralApotex Corporation1999-07-22Not applicableCanada
Apo-doxazosinTablet2 mgOralApotex Corporation1999-07-22Not applicableCanada
Apo-doxazosinTablet4 mgOralApotex Corporation1999-07-22Not applicableCanada
DoxazosinTablet1 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-31Not applicableUs
DoxazosinTablet2 mg/1OralCardinal Health2011-08-18Not applicableUs
DoxazosinTablet2 mg/1OralMylan Pharmaceuticals2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralAphena Pharma Solutions Tennessee, Inc.2000-10-20Not applicableUs
DoxazosinTablet1 mg/1OralRemedy Repack2014-12-012017-02-28Us00093 2070 01 nlmimage10 a743d3de
DoxazosinTablet1 mg/1OralA S Medication Solutions2000-10-202017-06-20Us
DoxazosinTablet2 mg/1OralPreferreed Pharmaceuticals Inc.2013-06-24Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DoxazosinTablet2 mg/1OralRemedy Repack2017-11-10Not applicableUs
International/Other Brands
Alfadil (Pfizer (Sweden)) / Cardenalin (Pfizer (Japan; discontinued)) / Cardular (Pfizer (Germany)) / Cardura-1 (Pfizer (Canada)) / Cardura-2 (Pfizer (Canada)) / Cardura-4 (Pfizer (Canada)) / Carduran (Pfizer (Brazil, Denmark, Norway, Spain)) / Diblocin (AstraZeneca (Germany)) / Normothen (Bioindustria (Italy)) / Supressin (Pfizer (Austria))
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cardura-1,2,and 4Doxazosin (1 mg) + Doxazosin (2 mg) + Doxazosin (4 mg)Kit; TabletOralAstra ZenecaNot applicableNot applicableCanada
Cardura-1,2,and 4Doxazosin (1 mg) + Doxazosin (2 mg) + Doxazosin (4 mg)Kit; TabletOralAstra ZenecaNot applicableNot applicableCanada
Cardura-1,2,and 4Doxazosin (1 mg) + Doxazosin (2 mg) + Doxazosin (4 mg)Kit; TabletOralAstra ZenecaNot applicableNot applicableCanada
Categories
UNII
NW1291F1W8
CAS number
74191-85-8
Weight
Average: 451.4751
Monoisotopic: 451.185568935
Chemical Formula
C23H25N5O5
InChI Key
RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
IUPAC Name
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1

Pharmacology

Indication

For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.

Structured Indications
Pharmacodynamics

Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.

Mechanism of action

Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 7
inhibitor
Human
Absorption

65%

Volume of distribution
Not Available
Protein binding

98%

Metabolism

Hepatic.

Route of elimination

On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.

Half life

22 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include hypotension. Oral LD50 is greater than 1000 mg/kg in mice and rats.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Doxazosin.Experimental
AbirateroneThe serum concentration of Doxazosin can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
AdrafinilDoxazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Doxazosin.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Doxazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Doxazosin is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Withdrawn
AmbrisentanDoxazosin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronDoxazosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineDoxazosin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amiloride.Approved
AmiodaroneThe metabolism of Doxazosin can be decreased when combined with Amiodarone.Approved, Investigational
AmitrazDoxazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Doxazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Doxazosin.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Doxazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Doxazosin.Approved, Investigational
AmrinoneDoxazosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amyl Nitrite.Approved
AnisodamineDoxazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Doxazosin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Apraclonidine.Approved
ArbutamineDoxazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolDoxazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Doxazosin.Approved, Investigational
ArmodafinilThe metabolism of Doxazosin can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Doxazosin.Approved, Investigational
ArtemetherThe metabolism of Doxazosin can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
AtomoxetineThe metabolism of Doxazosin can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Doxazosin.Approved
AzelnidipineDoxazosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.Approved
AzimilideDoxazosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Doxazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Doxazosin.Illicit
BarnidipineDoxazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Doxazosin.Approved, Investigational
BencyclaneDoxazosin may increase the hypotensive activities of Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Doxazosin.Approved
BenidipineDoxazosin may increase the hypotensive activities of Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Doxazosin.Withdrawn
BepridilDoxazosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BethanidineBethanidine may increase the hypotensive activities of Doxazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BietaserpineDoxazosin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostDoxazosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BitolterolDoxazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Doxazosin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BortezomibThe metabolism of Doxazosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Doxazosin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxazosin.Approved
BQ-123Doxazosin may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Doxazosin.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Doxazosin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxazosin.Approved, Investigational
BucindololBucindolol may increase the orthostatic hypotensive activities of Doxazosin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Doxazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.Approved
BunazosinDoxazosin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxazosin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BupropionThe metabolism of Doxazosin can be decreased when combined with Bupropion.Approved
CadralazineDoxazosin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineDoxazosin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.Approved
CandesartanDoxazosin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Candesartan cilexetil.Approved
CandoxatrilDoxazosin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Captopril.Approved
CarbamazepineThe metabolism of Doxazosin can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Doxazosin.Approved
CarboxyamidotriazoleDoxazosin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CaroverineDoxazosin may increase the hypotensive activities of Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Doxazosin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
CelecoxibThe metabolism of Doxazosin can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
ChloramphenicolThe metabolism of Doxazosin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Doxazosin can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doxazosin.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Doxazosin.Approved
CholecalciferolThe metabolism of Doxazosin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineDoxazosin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Cilazapril.Approved
CilnidipineDoxazosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Doxazosin can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Doxazosin can be decreased when combined with Cinacalcet.Approved
CinnarizineDoxazosin may increase the hypotensive activities of Cinnarizine.Approved, Investigational
CirazolineDoxazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe metabolism of Doxazosin can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Doxazosin can be decreased when combined with Clemastine.Approved
ClenbuterolDoxazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Clevidipine.Approved
ClobazamThe metabolism of Doxazosin can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Doxazosin.Approved, Investigational
ClomipramineThe metabolism of Doxazosin can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxazosin.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
ClotrimazoleThe metabolism of Doxazosin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Doxazosin.Approved
CobicistatThe serum concentration of Doxazosin can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Doxazosin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxazosin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Doxazosin.Approved, Investigational
CryptenamineDoxazosin may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideDoxazosin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideDoxazosin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.Approved
DabrafenibThe serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.Investigational
DarifenacinThe metabolism of Doxazosin can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineDoxazosin may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Doxazosin can be increased when it is combined with Darunavir.Approved
DebrisoquinDoxazosin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilDoxazosin may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Doxazosin can be decreased when combined with Delavirdine.Approved
DeserpidineDoxazosin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxazosin.Approved
DesipramineThe metabolism of Doxazosin can be decreased when combined with Desipramine.Approved
DetomidineDoxazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Doxazosin.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Diclofenamide.Approved
diethylnorspermineDoxazosin may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDoxazosin may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Doxazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Doxazosin can be decreased when combined with Diphenhydramine.Approved
DipivefrinDoxazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.Approved
DobutamineDoxazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineDoxazosin may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamideDoxazosin may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Doxazosin can be decreased when combined with Dosulepin.Approved
DotarizineDoxazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxazosin.Approved, Investigational
DronedaroneThe metabolism of Doxazosin can be decreased when combined with Dronedarone.Approved
DroxidopaDoxazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Doxazosin.Approved
EfavirenzThe metabolism of Doxazosin can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineDoxazosin may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Doxazosin can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Doxazosin.Approved, Vet Approved
EnalaprilatDoxazosin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineDoxazosin may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
EperisoneDoxazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineDoxazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineDoxazosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineDoxazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eplerenone.Approved
EpoprostenolDoxazosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eprosartan.Approved
ErgotamineDoxazosin may decrease the vasoconstricting activities of Ergotamine.Approved
Eslicarbazepine acetateThe metabolism of Doxazosin can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
EsomeprazoleThe metabolism of Doxazosin can be decreased when combined with Esomeprazole.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.Approved
EtilefrineDoxazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtravirineThe metabolism of Doxazosin can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Felodipine.Approved, Investigational
FendilineDoxazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamDoxazosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolDoxazosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidDoxazosin may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Doxazosin.Approved, Investigational
FluconazoleThe metabolism of Doxazosin can be decreased when combined with Fluconazole.Approved
FlunarizineDoxazosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Doxazosin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolDoxazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Doxazosin.Approved
FosphenytoinThe metabolism of Doxazosin can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Doxazosin.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.Approved, Vet Approved
GabapentinDoxazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilDoxazosin may increase the hypotensive activities of Gallopamil.Investigational
GemfibrozilThe metabolism of Doxazosin can be decreased when combined with Gemfibrozil.Approved
GuanabenzDoxazosin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelDoxazosin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineDoxazosin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineDoxazosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Guanfacine.Approved, Investigational
GuanoclorDoxazosin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzDoxazosin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanDoxazosin may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Doxazosin can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Doxazosin.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Doxazosin.Experimental
HexamethoniumDoxazosin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Doxazosin.Approved
HexoprenalineDoxazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineDoxazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Doxazosin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDoxazosin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Doxazosin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Doxazosin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Doxazosin.Withdrawn
IndinavirThe metabolism of Doxazosin can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Doxazosin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Doxazosin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Doxazosin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Doxazosin.Approved
IsoetarineDoxazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Doxazosin.Approved, Vet Approved
IsoniazidThe metabolism of Doxazosin can be decreased when combined with Isoniazid.Approved
IsoprenalineDoxazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Doxazosin.Approved
KetanserinDoxazosin may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Doxazosin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
LacidipineDoxazosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineDoxazosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Doxazosin.Investigational
LatanoprostDoxazosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Doxazosin.Approved
LercanidipineDoxazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Doxazosin.Approved, Investigational
LevodopaDoxazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Doxazosin.Approved, Investigational
LidoflazineDoxazosin may increase the hypotensive activities of Lidoflazine.Experimental
LinsidomineDoxazosin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Lisinopril.Approved, Investigational
LobeglitazoneThe metabolism of Doxazosin can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineDoxazosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Doxazosin can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Doxazosin can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Losartan.Approved
LuliconazoleThe serum concentration of Doxazosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Doxazosin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Doxazosin can be decreased when combined with Lumefantrine.Approved
MacitentanDoxazosin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateDoxazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineDoxazosin may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Doxazosin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mecamylamine.Approved
MedetomidineDoxazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineDoxazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
MetaraminolDoxazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Doxazosin can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Doxazosin.Approved
MethoserpidineDoxazosin may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.Approved
MethoxamineDoxazosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineDoxazosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Doxazosin.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Doxazosin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Doxazosin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
MetyrosineDoxazosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilDoxazosin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineDoxazosin may decrease the vasoconstricting activities of Midodrine.Approved
MidostaurinThe metabolism of Doxazosin can be decreased when combined with Midostaurin.Approved
MinaprineMinaprine may increase the hypotensive activities of Doxazosin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Doxazosin.Approved
MirabegronThe metabolism of Doxazosin can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Doxazosin.Investigational
MoclobemideThe metabolism of Doxazosin can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Doxazosin can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Doxazosin.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Doxazosin.Approved, Investigational
MoxonidineDoxazosin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineDoxazosin may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Doxazosin.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
NaftopidilDoxazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxazosin.Approved
NaphazolineDoxazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
NelfinavirThe metabolism of Doxazosin can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Doxazosin can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Doxazosin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Doxazosin.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nifedipine.Approved
NiguldipineDoxazosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Doxazosin can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineDoxazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineDoxazosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideDoxazosin may increase the hypotensive activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Doxazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Doxazosin.Approved
NitrendipineDoxazosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Doxazosin.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Doxazosin.Approved
NorepinephrineDoxazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineDoxazosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinDoxazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabDoxazosin may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Doxazosin.Withdrawn
OctopamineDoxazosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Doxazosin.Approved, Investigational
OlodaterolDoxazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatDoxazosin may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Doxazosin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineDoxazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumDoxazosin may increase the hypotensive activities of Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
OxyfedrineDoxazosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineDoxazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxazosin.Approved, Vet Approved
PanobinostatThe serum concentration of Doxazosin can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Doxazosin.Approved
ParoxetineThe metabolism of Doxazosin can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.Approved
Peginterferon alfa-2bThe serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
PentoliniumDoxazosin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Doxazosin.Approved, Investigational
PerhexilineDoxazosin may increase the hypotensive activities of Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Doxazosin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Doxazosin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Doxazosin.Approved
PhenoxybenzamineDoxazosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Doxazosin.Withdrawn
PhentolamineDoxazosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineDoxazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineDoxazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Doxazosin can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilDoxazosin may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumDoxazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doxazosin.Approved, Investigational
PirbuterolDoxazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Doxazosin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Doxazosin.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Doxazosin.Experimental
PolythiazideDoxazosin may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Doxazosin.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Doxazosin.Approved
PregabalinDoxazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolDoxazosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineDoxazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Doxazosin.Approved
ProcaterolDoxazosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineThe metabolism of Doxazosin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Doxazosin.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxazosin.Approved
PseudoephedrineDoxazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Doxazosin can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Doxazosin.Approved
RacepinephrineDoxazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineDoxazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Doxazosin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxazosin.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Doxazosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxazosin.Approved
RemikirenDoxazosin may increase the hypotensive activities of Remikiren.Approved
ReproterolDoxazosin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineDoxazosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Doxazosin.Approved, Investigational
RifampicinThe metabolism of Doxazosin can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxazosin.Approved, Investigational
RilmenidineDoxazosin may increase the hypotensive activities of Rilmenidine.Investigational
RimiterolDoxazosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Doxazosin is combined with Riociguat.Approved
RisedronateDoxazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneDoxazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronDoxazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineDoxazosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Doxazosin can be decreased when combined with Ritonavir.Approved, Investigational
RituximabDoxazosin may increase the hypotensive activities of Rituximab.Approved
RolapitantThe metabolism of Doxazosin can be decreased when combined with Rolapitant.Approved
RomifidineDoxazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Doxazosin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxazosin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Doxazosin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Doxazosin.Approved
SafrazineSafrazine may increase the hypotensive activities of Doxazosin.Withdrawn
SalbutamolDoxazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolDoxazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanDoxazosin may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Doxazosin.Approved, Investigational, Vet Approved
SelexipagDoxazosin may increase the hypotensive activities of Selexipag.Approved
SertralineThe metabolism of Doxazosin can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxazosin.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.Approved
SitaxentanDoxazosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Doxazosin.Approved
SolabegronDoxazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
SpiraprilDoxazosin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.Approved
StiripentolThe metabolism of Doxazosin can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Doxazosin.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxazosin.Approved, Investigational
SynephrineDoxazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Doxazosin.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Doxazosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Telmisartan.Approved, Investigational
TemocaprilDoxazosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Terazosin.Approved
TerbinafineThe metabolism of Doxazosin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineDoxazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerlipressinDoxazosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineDoxazosin may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
TetrahydropalmatineDoxazosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Doxazosin.Approved, Investigational, Withdrawn
TheodrenalineDoxazosin may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ThioridazineThe metabolism of Doxazosin can be decreased when combined with Thioridazine.Approved, Withdrawn
TiboloneDoxazosin may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Doxazosin can be decreased when combined with Ticlopidine.Approved
TicrynafenDoxazosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
TipranavirThe metabolism of Doxazosin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.Approved
TolazolineDoxazosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxazosin.Approved, Withdrawn
Tolfenamic AcidDoxazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolonidineDoxazosin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Doxazosin.Approved
TopiramateThe metabolism of Doxazosin can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxazosin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Doxazosin.Approved
TranilastDoxazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.Experimental
TranylcypromineThe metabolism of Doxazosin can be decreased when combined with Tranylcypromine.Approved
TravoprostDoxazosin may increase the hypotensive activities of Travoprost.Approved
TreprostinilDoxazosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Doxazosin.Approved, Investigational, Nutraceutical
TretoquinolDoxazosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.Approved
TrichlormethiazideDoxazosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinDoxazosin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanDoxazosin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TulobuterolDoxazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
UnoprostoneDoxazosin may increase the hypotensive activities of Unoprostone.Approved
UrapidilDoxazosin may increase the hypotensive activities of Urapidil.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Doxazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Doxazosin.Approved
VenlafaxineThe metabolism of Doxazosin can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Verapamil.Approved
VincamineDoxazosin may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.Approved, Investigational
VinpocetineDoxazosin may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Doxazosin can be decreased when combined with Voriconazole.Approved, Investigational
XamoterolDoxazosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideDoxazosin may increase the hypotensive activities of Xipamide.Experimental
XylazineDoxazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineDoxazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Doxazosin may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Doxazosin.Approved, Vet Approved
ZiconotideDoxazosin may increase the hypotensive activities of Ziconotide.Approved
ZiprasidoneThe metabolism of Doxazosin can be decreased when combined with Ziprasidone.Approved
ZofenoprilDoxazosin may increase the hypotensive activities of Zofenopril.Experimental
ZucapsaicinThe metabolism of Doxazosin can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

References

Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, "Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines." U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301]
External Links
Human Metabolome Database
HMDB14728
KEGG Drug
D07874
KEGG Compound
C06970
PubChem Compound
3157
PubChem Substance
46506825
ChemSpider
3045
BindingDB
86731
ChEBI
4708
ChEMBL
CHEMBL707
Therapeutic Targets Database
DAP000381
PharmGKB
PA449407
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Doxazosin
ATC Codes
C02CA04 — Doxazosin
AHFS Codes
  • 24:20.00 — Alpha-adrenergic Blocking Agents
FDA label
Download (511 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCocaine Abuse / Dependence, Cocaine / Substance Abuse1
1CompletedNot AvailableSubstance-Related Disorders1
1CompletedBasic ScienceAmphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders1
1CompletedTreatmentDependence, Cocaine1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHealthy Volunteers1
1RecruitingTreatmentDependence, Cocaine1
1RecruitingTreatmentPTSD1
1, 2CompletedTreatmentMethamphetamine or Cocaine Dependence1
1, 2Not Yet RecruitingTreatmentAlcohol Use Disorder (AUD) / PTSD1
2Active Not RecruitingTreatmentSmoking1
2CompletedDiagnosticDependence, Cocaine1
2CompletedTreatmentAlcohol Dependence / Feeling Anxious1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2Not Yet RecruitingTreatmentAlcoholism1
2Not Yet RecruitingTreatmentStress Disorders, Post-Traumatic1
2RecruitingTreatmentAlcohol Use Disorders (AUD) / Posttraumatic Stress Disorders / PTSD1
2RecruitingTreatmentDependence, Cocaine1
2, 3RecruitingTreatmentHypertensive1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / Hypercholesterolaemia / Hypertensive / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedTreatmentProstatic Hyperplasia / Prostatic Hypertrophy, Benign1
3RecruitingTreatmentParaganglioma / Pheochromocytomas1
3Unknown StatusTreatmentRenal Stones1
4Active Not RecruitingTreatmentHypertension, Resistant to Conventional Therapy1
4CompletedBasic ScienceIdiopathic Dilated Cardiomyopathy1
4CompletedTreatmentHigh Blood Pressure1
4CompletedTreatmentHypertensive4
4CompletedTreatmentStress Disorders, Post-Traumatic1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentPheochromocytomas1
4Unknown StatusPreventionDiabetic Nephropathies1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
Not AvailableCompletedBasic ScienceBenign Prostatic Hyperplasia (BPH)1
Not AvailableTerminatedTreatmentHypertensive / Microvascular Angina1
Not AvailableTerminatedTreatmentProstatic Hyperplasia / Urinary Retention1

Pharmacoeconomics

Manufacturers
  • Pfizer inc
  • Pfizer laboratories div pfizer inc
  • Actavis elizabeth llc
  • Apotex inc
  • Dava pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, multilayer, extended releaseOral4 mg/1
Tablet, multilayer, extended releaseOral8 mg/1
TabletOral1 mg
Kit; tabletOral
TabletOral2 mg
TabletOral4 mg
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
TabletOral1 mg/1
Prices
Unit descriptionCostUnit
Cardura XL 4 mg 24 Hour tablet2.22USD tablet
Cardura xl 8 mg tablet2.04USD tablet
Cardura xl 4 mg tablet1.94USD tablet
Cardura 8 mg tablet1.93USD tablet
Cardura 4 mg tablet1.89USD tablet
Cardura 2 mg tablet1.81USD tablet
Cardura 1 mg tablet1.72USD tablet
Doxazosin mesylate 8 mg tablet1.04USD tablet
Cardura 4 mg Tablet1.0USD tablet
Doxazosin mesylate 4 mg tablet0.99USD tablet
Doxazosin mesylate 1 mg tablet0.94USD tablet
Doxazosin mesylate 2 mg tablet0.94USD tablet
Cardura 2 mg Tablet0.77USD tablet
Cardura 1 mg Tablet0.64USD tablet
Apo-Doxazosin 4 mg Tablet0.56USD tablet
Mylan-Doxazosin 4 mg Tablet0.56USD tablet
Novo-Doxazosin 4 mg Tablet0.56USD tablet
Pms-Doxazosin 4 mg Tablet0.56USD tablet
Apo-Doxazosin 2 mg Tablet0.43USD tablet
Mylan-Doxazosin 2 mg Tablet0.43USD tablet
Novo-Doxazosin 2 mg Tablet0.43USD tablet
Pms-Doxazosin 2 mg Tablet0.43USD tablet
Apo-Doxazosin 1 mg Tablet0.36USD tablet
Mylan-Doxazosin 1 mg Tablet0.36USD tablet
Novo-Doxazosin 1 mg Tablet0.36USD tablet
Pms-Doxazosin 1 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)289-290 °CNot Available
water solubility24 mg/LNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.79 mg/mLALOGPS
logP2.53ALOGPS
logP2.14ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)12.67ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.64 m3·mol-1ChemAxon
Polarizability46.63 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9627
Caco-2 permeable+0.7863
P-glycoprotein substrateSubstrate0.7303
P-glycoprotein inhibitor INon-inhibitor0.7391
P-glycoprotein inhibitor IINon-inhibitor0.9528
Renal organic cation transporterNon-inhibitor0.6909
CYP450 2C9 substrateNon-substrate0.9011
CYP450 2D6 substrateNon-substrate0.8195
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateNon-inhibitor0.8293
CYP450 2C9 inhibitorNon-inhibitor0.9161
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.9084
CYP450 3A4 inhibitorNon-inhibitor0.8002
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9078
Ames testNon AMES toxic0.5648
CarcinogenicityNon-carcinogens0.8905
BiodegradationNot ready biodegradable0.9854
Rat acute toxicity2.1954 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8602
hERG inhibition (predictor II)Inhibitor0.823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0010900000-9601aa919c95799ec009
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0kei-0981100000-a9ee3121ba6832366f8e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0970000000-5261f1bc60ceee4364de
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0950000000-f649236044e4e2a5de38
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1920000000-86655cc3bb892d757068
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1900000000-88bca2ddf2930fa0c468
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0000900000-449254642300c1324285
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0002900000-3097c8a3403b52610918
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0079100000-06d36a9b7afe6cf0c6e9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000t-1091000000-cbd9b2106818ef5fd2ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1190000000-a1c84b0c3657d8000e35
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1390000000-e802cb93ca8d6934ee96

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Quinazolinamines / Benzo-1,4-dioxanes / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Para dioxins / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 8 more
Substituents
N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Benzo-1,4-dioxane / Benzodioxane / Quinazoline / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, monocarboxylic acid amide, aromatic amine, quinazolines, benzodioxine, N-acylpiperazine (CHEBI:4708)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8. [PubMed:15573147]
  2. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427]
  3. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264]
  4. Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93. [PubMed:9205965]
  5. Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5. [PubMed:16225542]
  6. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123]
  7. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143]
  8. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH6
Uniprot ID
Q9H252
Uniprot Name
Potassium voltage-gated channel subfamily H member 6
Molecular Weight
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH7
Uniprot ID
Q9NS40
Uniprot Name
Potassium voltage-gated channel subfamily H member 7
Molecular Weight
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34